Posfrea

Overview

palonosetron

5-HT3 antagonist

• prolongs QT interval (known)
• serotonergic effects

Contraindicated

• apomorphine
Posfrea (palonosetron)

+

apomorphine

1 interaction

Contraindicated

palonosetron + apomorphine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound hypotension, loss of consciousness (additive effects)

• cisapride
Posfrea (palonosetron)

+

cisapride

1 interaction

Contraindicated

palonosetron + cisapride

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Posfrea (palonosetron)

+

domperidone

1 interaction

Contraindicated

palonosetron + domperidone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Posfrea (palonosetron)

+

dronedarone

1 interaction

Contraindicated

palonosetron + dronedarone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Posfrea (palonosetron)

+

levoketoconazole

1 interaction

Contraindicated

palonosetron + levoketoconazole

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pimozide
Posfrea (palonosetron)

+

pimozide

1 interaction

Contraindicated

palonosetron + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• thioridazine
Posfrea (palonosetron)

+

thioridazine

1 interaction

Contraindicated

palonosetron + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• adagrasib
Posfrea (palonosetron)

+

adagrasib

1 interaction

Avoid/Use Alternative

palonosetron + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alfentanil
Posfrea (palonosetron)

+

alfentanil

1 interaction

Avoid/Use Alternative

palonosetron + alfentanil

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• amiodarone
Posfrea (palonosetron)

+

amiodarone

1 interaction

Avoid/Use Alternative

palonosetron + amiodarone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amphetamine
Posfrea (palonosetron)

+

amphetamine

1 interaction

Avoid/Use Alternative

palonosetron + amphetamine

consider alternative or decr. amphetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• anagrelide
Posfrea (palonosetron)

+

anagrelide

1 interaction

Avoid/Use Alternative

palonosetron + anagrelide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arsenic trioxide
Posfrea (palonosetron)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

palonosetron + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Posfrea (palonosetron)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

palonosetron + artemether/ lumefantrine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Posfrea (palonosetron)

+

asenapine

1 interaction

Avoid/Use Alternative

palonosetron + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• azithromycin
Posfrea (palonosetron)

+

azithromycin

1 interaction

Avoid/Use Alternative

palonosetron + azithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Posfrea (palonosetron)

+

bedaquiline

1 interaction

Avoid/Use Alternative

palonosetron + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• buprenorphine
Posfrea (palonosetron)

+

buprenorphine

1 interaction

Avoid/Use Alternative

palonosetron + buprenorphine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• butorphanol
Posfrea (palonosetron)

+

butorphanol

1 interaction

Avoid/Use Alternative

palonosetron + butorphanol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• cabozantinib
Posfrea (palonosetron)

+

cabozantinib

1 interaction

Avoid/Use Alternative

palonosetron + cabozantinib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chloroquine
Posfrea (palonosetron)

+

chloroquine

1 interaction

Avoid/Use Alternative

palonosetron + chloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• citalopram
Posfrea (palonosetron)

+

citalopram

1 interaction

Avoid/Use Alternative

palonosetron + citalopram

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• clarithromycin
Posfrea (palonosetron)

+

clarithromycin

1 interaction

Avoid/Use Alternative

palonosetron + clarithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clomipramine
Posfrea (palonosetron)

+

clomipramine

1 interaction

Avoid/Use Alternative

palonosetron + clomipramine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• codeine
Posfrea (palonosetron)

+

codeine

1 interaction

Avoid/Use Alternative

palonosetron + codeine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• crizotinib
Posfrea (palonosetron)

+

crizotinib

1 interaction

Avoid/Use Alternative

palonosetron + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cyclobenzaprine
Posfrea (palonosetron)

+

cyclobenzaprine

1 interaction

Avoid/Use Alternative

palonosetron + cyclobenzaprine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• degarelix
Posfrea (palonosetron)

+

degarelix

1 interaction

Avoid/Use Alternative

palonosetron + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Posfrea (palonosetron)

+

desflurane

1 interaction

Avoid/Use Alternative

palonosetron + desflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Posfrea (palonosetron)

+

desipramine

1 interaction

Avoid/Use Alternative

palonosetron + desipramine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• desvenlafaxine
Posfrea (palonosetron)

+

desvenlafaxine

1 interaction

Avoid/Use Alternative

palonosetron + desvenlafaxine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dexmedetomidine
Posfrea (palonosetron)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

palonosetron + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Posfrea (palonosetron)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

palonosetron + dexmedetomidine injection

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dextroamphetamine
Posfrea (palonosetron)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

palonosetron + dextroamphetamine

consider alternative or decr. dextroamphetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dihydrocodeine
Posfrea (palonosetron)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

palonosetron + dihydrocodeine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• disopyramide
Posfrea (palonosetron)

+

disopyramide

1 interaction

Avoid/Use Alternative

palonosetron + disopyramide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dofetilide
Posfrea (palonosetron)

+

dofetilide

1 interaction

Avoid/Use Alternative

palonosetron + dofetilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Posfrea (palonosetron)

+

droperidol

1 interaction

Avoid/Use Alternative

palonosetron + droperidol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• duloxetine
Posfrea (palonosetron)

+

duloxetine

1 interaction

Avoid/Use Alternative

palonosetron + duloxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• efavirenz
Posfrea (palonosetron)

+

efavirenz

1 interaction

Avoid/Use Alternative

palonosetron + efavirenz

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• encorafenib
Posfrea (palonosetron)

+

encorafenib

1 interaction

Avoid/Use Alternative

palonosetron + encorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• entrectinib
Posfrea (palonosetron)

+

entrectinib

1 interaction

Avoid/Use Alternative

palonosetron + entrectinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ephedra
Posfrea (palonosetron)

+

ephedra

1 interaction

Avoid/Use Alternative

palonosetron + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Posfrea (palonosetron)

+

eribulin

1 interaction

Avoid/Use Alternative

palonosetron + eribulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Posfrea (palonosetron)

+

erythromycin

1 interaction

Avoid/Use Alternative

palonosetron + erythromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• escitalopram
Posfrea (palonosetron)

+

escitalopram

1 interaction

Avoid/Use Alternative

palonosetron + escitalopram

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• etrasimod
Posfrea (palonosetron)

+

etrasimod

1 interaction

Avoid/Use Alternative

palonosetron + etrasimod

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• fentanyl
Posfrea (palonosetron)

+

fentanyl

1 interaction

Avoid/Use Alternative

palonosetron + fentanyl

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• fexinidazole
Posfrea (palonosetron)

+

fexinidazole

1 interaction

Avoid/Use Alternative

palonosetron + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after palonosetron D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Posfrea (palonosetron)

+

flecainide

1 interaction

Avoid/Use Alternative

palonosetron + flecainide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Posfrea (palonosetron)

+

fluoxetine

1 interaction

Avoid/Use Alternative

palonosetron + fluoxetine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• fluvoxamine
Posfrea (palonosetron)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

palonosetron + fluvoxamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• foscarnet
Posfrea (palonosetron)

+

foscarnet

1 interaction

Avoid/Use Alternative

palonosetron + foscarnet

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepirone
Posfrea (palonosetron)

+

gepirone

1 interaction

Avoid/Use Alternative

palonosetron + gepirone

use alternative or monitor ECG, electrolytes, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• givinostat
Posfrea (palonosetron)

+

givinostat

1 interaction

Avoid/Use Alternative

palonosetron + givinostat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Posfrea (palonosetron)

+

glasdegib

1 interaction

Avoid/Use Alternative

palonosetron + glasdegib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Posfrea (palonosetron)

+

goserelin

1 interaction

Avoid/Use Alternative

palonosetron + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• granisetron
Posfrea (palonosetron)

+

granisetron

1 interaction

Avoid/Use Alternative

palonosetron + granisetron

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome, other adverse effects (additive effects, duplicate tx)

• grapefruit
Posfrea (palonosetron)

+

grapefruit

1 interaction

Avoid/Use Alternative

palonosetron + grapefruit

use alternative or monitor ECG w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Posfrea (palonosetron)

+

histrelin

1 interaction

Avoid/Use Alternative

palonosetron + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• hydrocodone
Posfrea (palonosetron)

+

hydrocodone

1 interaction

Avoid/Use Alternative

palonosetron + hydrocodone

use alternative or monitor ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• hydromorphone
Posfrea (palonosetron)

+

hydromorphone

1 interaction

Avoid/Use Alternative

palonosetron + hydromorphone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• hydroxychloroquine
Posfrea (palonosetron)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

palonosetron + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Posfrea (palonosetron)

+

ibutilide

1 interaction

Avoid/Use Alternative

palonosetron + ibutilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• iloperidone
Posfrea (palonosetron)

+

iloperidone

1 interaction

Avoid/Use Alternative

palonosetron + iloperidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• inotuzumab ozogamicin
Posfrea (palonosetron)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

palonosetron + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isocarboxazid
Posfrea (palonosetron)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

palonosetron + isocarboxazid

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• isoflurane
Posfrea (palonosetron)

+

isoflurane

1 interaction

Avoid/Use Alternative

palonosetron + isoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoniazid
Posfrea (palonosetron)

+

isoniazid

1 interaction

Avoid/Use Alternative

palonosetron + isoniazid

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, isoniazid inhibits monoamine oxidase)

• ivabradine
Posfrea (palonosetron)

+

ivabradine

1 interaction

Avoid/Use Alternative

palonosetron + ivabradine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ivosidenib
Posfrea (palonosetron)

+

ivosidenib

1 interaction

Avoid/Use Alternative

palonosetron + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lefamulin
Posfrea (palonosetron)

+

lefamulin

1 interaction

Avoid/Use Alternative

palonosetron + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• leuprolide
Posfrea (palonosetron)

+

leuprolide

1 interaction

Avoid/Use Alternative

palonosetron + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Posfrea (palonosetron)

+

levofloxacin

1 interaction

Avoid/Use Alternative

palonosetron + levofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levomilnacipran
Posfrea (palonosetron)

+

levomilnacipran

1 interaction

Avoid/Use Alternative

palonosetron + levomilnacipran

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• levorphanol
Posfrea (palonosetron)

+

levorphanol

1 interaction

Avoid/Use Alternative

palonosetron + levorphanol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• linezolid
Posfrea (palonosetron)

+

linezolid

1 interaction

Avoid/Use Alternative

palonosetron + linezolid

use alternative or hold palonosetron if urgent use; monitor serotonin syndrome sx x2wk after palonosetron D/C or 24h after last linezolid dose: combo may incr. risk of serotonin syndrome (additive effects, linezolid reversibly inhibits monoamine oxidase)

• lisdexamfetamine
Posfrea (palonosetron)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

palonosetron + lisdexamfetamine

consider alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• lithium
Posfrea (palonosetron)

+

lithium

1 interaction

Avoid/Use Alternative

palonosetron + lithium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• lonafarnib
Posfrea (palonosetron)

+

lonafarnib

1 interaction

Avoid/Use Alternative

palonosetron + lonafarnib

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• loperamide
Posfrea (palonosetron)

+

loperamide

1 interaction

Avoid/Use Alternative

palonosetron + loperamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Posfrea (palonosetron)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

palonosetron + lopinavir/ ritonavir

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• macimorelin
Posfrea (palonosetron)

+

macimorelin

1 interaction

Avoid/Use Alternative

palonosetron + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• meperidine
Posfrea (palonosetron)

+

meperidine

1 interaction

Avoid/Use Alternative

palonosetron + meperidine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• metaxalone
Posfrea (palonosetron)

+

metaxalone

1 interaction

Avoid/Use Alternative

palonosetron + metaxalone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methadone
Posfrea (palonosetron)

+

methadone

1 interaction

Avoid/Use Alternative

palonosetron + methadone

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• methamphetamine
Posfrea (palonosetron)

+

methamphetamine

1 interaction

Avoid/Use Alternative

palonosetron + methamphetamine

consider alternative or decr. methamphetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methylene blue oral
Posfrea (palonosetron)

+

methylene blue oral

1 interaction

Avoid/Use Alternative

palonosetron + methylene blue oral

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• mifepristone
Posfrea (palonosetron)

+

mifepristone

1 interaction

Avoid/Use Alternative

palonosetron + mifepristone

use alternative or monitor ECG if daily mifepristone use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• milnacipran
Posfrea (palonosetron)

+

milnacipran

1 interaction

Avoid/Use Alternative

palonosetron + milnacipran

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• mirtazapine
Posfrea (palonosetron)

+

mirtazapine

1 interaction

Avoid/Use Alternative

palonosetron + mirtazapine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• mobocertinib
Posfrea (palonosetron)

+

mobocertinib

1 interaction

Avoid/Use Alternative

palonosetron + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• morphine
Posfrea (palonosetron)

+

morphine

1 interaction

Avoid/Use Alternative

palonosetron + morphine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• moxifloxacin
Posfrea (palonosetron)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

palonosetron + moxifloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nalbuphine
Posfrea (palonosetron)

+

nalbuphine

1 interaction

Avoid/Use Alternative

palonosetron + nalbuphine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nilotinib
Posfrea (palonosetron)

+

nilotinib

1 interaction

Avoid/Use Alternative

palonosetron + nilotinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nortriptyline
Posfrea (palonosetron)

+

nortriptyline

1 interaction

Avoid/Use Alternative

palonosetron + nortriptyline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• oliceridine
Posfrea (palonosetron)

+

oliceridine

1 interaction

Avoid/Use Alternative

palonosetron + oliceridine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• ondansetron
Posfrea (palonosetron)

+

ondansetron

1 interaction

Avoid/Use Alternative

palonosetron + ondansetron

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome, other adverse effects (additive effects, duplicate tx)

• opium
Posfrea (palonosetron)

+

opium

1 interaction

Avoid/Use Alternative

palonosetron + opium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• osimertinib
Posfrea (palonosetron)

+

osimertinib

1 interaction

Avoid/Use Alternative

palonosetron + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Posfrea (palonosetron)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

palonosetron + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxycodone
Posfrea (palonosetron)

+

oxycodone

1 interaction

Avoid/Use Alternative

palonosetron + oxycodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• oxymorphone
Posfrea (palonosetron)

+

oxymorphone

1 interaction

Avoid/Use Alternative

palonosetron + oxymorphone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ozanimod
Posfrea (palonosetron)

+

ozanimod

1 interaction

Avoid/Use Alternative

palonosetron + ozanimod

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Posfrea (palonosetron)

+

pacritinib

1 interaction

Avoid/Use Alternative

palonosetron + pacritinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paliperidone
Posfrea (palonosetron)

+

paliperidone

1 interaction

Avoid/Use Alternative

palonosetron + paliperidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• panobinostat
Posfrea (palonosetron)

+

panobinostat

1 interaction

Avoid/Use Alternative

palonosetron + panobinostat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paroxetine
Posfrea (palonosetron)

+

paroxetine

1 interaction

Avoid/Use Alternative

palonosetron + paroxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• pazopanib
Posfrea (palonosetron)

+

pazopanib

1 interaction

Avoid/Use Alternative

palonosetron + pazopanib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentamidine
Posfrea (palonosetron)

+

pentamidine

1 interaction

Avoid/Use Alternative

palonosetron + pentamidine

use alternative or monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentazocine
Posfrea (palonosetron)

+

pentazocine

1 interaction

Avoid/Use Alternative

palonosetron + pentazocine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• phenelzine
Posfrea (palonosetron)

+

phenelzine

1 interaction

Avoid/Use Alternative

palonosetron + phenelzine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• phenobarbital
Posfrea (palonosetron)

+

phenobarbital

1 interaction

Avoid/Use Alternative

palonosetron + phenobarbital

avoid combo if neonatal seizure use; otherwise, monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pimavanserin
Posfrea (palonosetron)

+

pimavanserin

1 interaction

Avoid/Use Alternative

palonosetron + pimavanserin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pitolisant
Posfrea (palonosetron)

+

pitolisant

1 interaction

Avoid/Use Alternative

palonosetron + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Posfrea (palonosetron)

+

ponesimod

1 interaction

Avoid/Use Alternative

palonosetron + ponesimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• procainamide
Posfrea (palonosetron)

+

procainamide

1 interaction

Avoid/Use Alternative

palonosetron + procainamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• procarbazine
Posfrea (palonosetron)

+

procarbazine

1 interaction

Avoid/Use Alternative

palonosetron + procarbazine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, procarbazine inhibits monoamine oxidase)

• propafenone
Posfrea (palonosetron)

+

propafenone

1 interaction

Avoid/Use Alternative

palonosetron + propafenone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quetiapine
Posfrea (palonosetron)

+

quetiapine

1 interaction

Avoid/Use Alternative

palonosetron + quetiapine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (antiarrhythmic)
Posfrea (palonosetron)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

palonosetron + quinidine (antiarrhythmic)

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Posfrea (palonosetron)

+

quinine

1 interaction

Avoid/Use Alternative

palonosetron + quinine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Posfrea (palonosetron)

+

quizartinib

1 interaction

Avoid/Use Alternative

palonosetron + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rasagiline
Posfrea (palonosetron)

+

rasagiline

1 interaction

Avoid/Use Alternative

palonosetron + rasagiline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• remifentanil
Posfrea (palonosetron)

+

remifentanil

1 interaction

Avoid/Use Alternative

palonosetron + remifentanil

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• revumenib
Posfrea (palonosetron)

+

revumenib

1 interaction

Avoid/Use Alternative

palonosetron + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Posfrea (palonosetron)

+

ribociclib

1 interaction

Avoid/Use Alternative

palonosetron + ribociclib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rilpivirine
Posfrea (palonosetron)

+

rilpivirine

1 interaction

Avoid/Use Alternative

palonosetron + rilpivirine

consider alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rucaparib
Posfrea (palonosetron)

+

rucaparib

1 interaction

Avoid/Use Alternative

palonosetron + rucaparib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• safinamide
Posfrea (palonosetron)

+

safinamide

1 interaction

Avoid/Use Alternative

palonosetron + safinamide

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• selegiline
Posfrea (palonosetron)

+

selegiline

1 interaction

Avoid/Use Alternative

palonosetron + selegiline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• selegiline transdermal
Posfrea (palonosetron)

+

selegiline transdermal

1 interaction

Avoid/Use Alternative

palonosetron + selegiline transdermal

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sertraline
Posfrea (palonosetron)

+

sertraline

1 interaction

Avoid/Use Alternative

palonosetron + sertraline

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• sevoflurane
Posfrea (palonosetron)

+

sevoflurane

1 interaction

Avoid/Use Alternative

palonosetron + sevoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• siponimod
Posfrea (palonosetron)

+

siponimod

1 interaction

Avoid/Use Alternative

palonosetron + siponimod

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• solifenacin
Posfrea (palonosetron)

+

solifenacin

1 interaction

Avoid/Use Alternative

palonosetron + solifenacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sorafenib
Posfrea (palonosetron)

+

sorafenib

1 interaction

Avoid/Use Alternative

palonosetron + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Posfrea (palonosetron)

+

sotalol

1 interaction

Avoid/Use Alternative

palonosetron + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sufentanil
Posfrea (palonosetron)

+

sufentanil

1 interaction

Avoid/Use Alternative

palonosetron + sufentanil

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• tapentadol
Posfrea (palonosetron)

+

tapentadol

1 interaction

Avoid/Use Alternative

palonosetron + tapentadol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• tetrabenazine
Posfrea (palonosetron)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

palonosetron + tetrabenazine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• toremifene
Posfrea (palonosetron)

+

toremifene

1 interaction

Avoid/Use Alternative

palonosetron + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Posfrea (palonosetron)

+

tramadol

1 interaction

Avoid/Use Alternative

palonosetron + tramadol

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• tranylcypromine
Posfrea (palonosetron)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

palonosetron + tranylcypromine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• trazodone
Posfrea (palonosetron)

+

trazodone

1 interaction

Avoid/Use Alternative

palonosetron + trazodone

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• trimipramine
Posfrea (palonosetron)

+

trimipramine

1 interaction

Avoid/Use Alternative

palonosetron + trimipramine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• triptorelin
Posfrea (palonosetron)

+

triptorelin

1 interaction

Avoid/Use Alternative

palonosetron + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• vandetanib
Posfrea (palonosetron)

+

vandetanib

1 interaction

Avoid/Use Alternative

palonosetron + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• venlafaxine
Posfrea (palonosetron)

+

venlafaxine

1 interaction

Avoid/Use Alternative

palonosetron + venlafaxine

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• vilazodone
Posfrea (palonosetron)

+

vilazodone

1 interaction

Avoid/Use Alternative

palonosetron + vilazodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• vortioxetine
Posfrea (palonosetron)

+

vortioxetine

1 interaction

Avoid/Use Alternative

palonosetron + vortioxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• yohimbe
Posfrea (palonosetron)

+

yohimbe

1 interaction

Avoid/Use Alternative

palonosetron + yohimbe

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, yohimbe inhibits monoamine oxidase)

• ziprasidone
Posfrea (palonosetron)

+

ziprasidone

1 interaction

Avoid/Use Alternative

palonosetron + ziprasidone

use alternative or monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

Monitor/Modify Tx

• 5-HTP
Posfrea (palonosetron)

+

5-HTP

1 interaction

Monitor/Modify Tx

palonosetron + 5-HTP

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• albuterol
Posfrea (palonosetron)

+

albuterol

1 interaction

Monitor/Modify Tx

palonosetron + albuterol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Posfrea (palonosetron)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + albuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alfuzosin
Posfrea (palonosetron)

+

alfuzosin

1 interaction

Monitor/Modify Tx

palonosetron + alfuzosin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• almotriptan
Posfrea (palonosetron)

+

almotriptan

1 interaction

Monitor/Modify Tx

palonosetron + almotriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• amisulpride
Posfrea (palonosetron)

+

amisulpride

1 interaction

Monitor/Modify Tx

palonosetron + amisulpride

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Posfrea (palonosetron)

+

amitriptyline

1 interaction

Monitor/Modify Tx

palonosetron + amitriptyline

monitor ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias, serotonin syndrome (additive effects)

• amoxapine
Posfrea (palonosetron)

+

amoxapine

1 interaction

Monitor/Modify Tx

palonosetron + amoxapine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• apalutamide
Posfrea (palonosetron)

+

apalutamide

1 interaction

Monitor/Modify Tx

palonosetron + apalutamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arformoterol inhaled
Posfrea (palonosetron)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + arformoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asciminib
Posfrea (palonosetron)

+

asciminib

1 interaction

Monitor/Modify Tx

palonosetron + asciminib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• berotralstat
Posfrea (palonosetron)

+

berotralstat

1 interaction

Monitor/Modify Tx

palonosetron + berotralstat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bromocriptine
Posfrea (palonosetron)

+

bromocriptine

1 interaction

Monitor/Modify Tx

palonosetron + bromocriptine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• buspirone
Posfrea (palonosetron)

+

buspirone

1 interaction

Monitor/Modify Tx

palonosetron + buspirone

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• carbamazepine
Posfrea (palonosetron)

+

carbamazepine

1 interaction

Monitor/Modify Tx

palonosetron + carbamazepine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ceritinib
Posfrea (palonosetron)

+

ceritinib

1 interaction

Monitor/Modify Tx

palonosetron + ceritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Posfrea (palonosetron)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

palonosetron + chlorpromazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ciprofloxacin
Posfrea (palonosetron)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

palonosetron + ciprofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clofazimine
Posfrea (palonosetron)

+

clofazimine

1 interaction

Monitor/Modify Tx

palonosetron + clofazimine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clozapine
Posfrea (palonosetron)

+

clozapine

1 interaction

Monitor/Modify Tx

palonosetron + clozapine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cocaine
Posfrea (palonosetron)

+

cocaine

1 interaction

Monitor/Modify Tx

palonosetron + cocaine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dasatinib
Posfrea (palonosetron)

+

dasatinib

1 interaction

Monitor/Modify Tx

palonosetron + dasatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• deutetrabenazine
Posfrea (palonosetron)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

palonosetron + deutetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmethylphenidate
Posfrea (palonosetron)

+

dexmethylphenidate

1 interaction

Monitor/Modify Tx

palonosetron + dexmethylphenidate

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dextromethorphan
Posfrea (palonosetron)

+

dextromethorphan

1 interaction

Monitor/Modify Tx

palonosetron + dextromethorphan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dihydroergotamine
Posfrea (palonosetron)

+

dihydroergotamine

1 interaction

Monitor/Modify Tx

palonosetron + dihydroergotamine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• donepezil
Posfrea (palonosetron)

+

donepezil

1 interaction

Monitor/Modify Tx

palonosetron + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxepin
Posfrea (palonosetron)

+

doxepin

1 interaction

Monitor/Modify Tx

palonosetron + doxepin

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• doxepin topical
Posfrea (palonosetron)

+

doxepin topical

1 interaction

Monitor/Modify Tx

palonosetron + doxepin topical

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• eletriptan
Posfrea (palonosetron)

+

eletriptan

1 interaction

Monitor/Modify Tx

palonosetron + eletriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• eliglustat
Posfrea (palonosetron)

+

eliglustat

1 interaction

Monitor/Modify Tx

palonosetron + eliglustat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Posfrea (palonosetron)

+

epirubicin

1 interaction

Monitor/Modify Tx

palonosetron + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ergotamine
Posfrea (palonosetron)

+

ergotamine

1 interaction

Monitor/Modify Tx

palonosetron + ergotamine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• fenfluramine
Posfrea (palonosetron)

+

fenfluramine

1 interaction

Monitor/Modify Tx

palonosetron + fenfluramine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• fingolimod
Posfrea (palonosetron)

+

fingolimod

1 interaction

Monitor/Modify Tx

palonosetron + fingolimod

monitor ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Posfrea (palonosetron)

+

fluconazole

1 interaction

Monitor/Modify Tx

palonosetron + fluconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Posfrea (palonosetron)

+

fluorouracil

1 interaction

Monitor/Modify Tx

palonosetron + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• formoterol inhaled
Posfrea (palonosetron)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + formoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fostemsavir
Posfrea (palonosetron)

+

fostemsavir

1 interaction

Monitor/Modify Tx

palonosetron + fostemsavir

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• frovatriptan
Posfrea (palonosetron)

+

frovatriptan

1 interaction

Monitor/Modify Tx

palonosetron + frovatriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• gemtuzumab ozogamicin
Posfrea (palonosetron)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

palonosetron + gemtuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Posfrea (palonosetron)

+

gilteritinib

1 interaction

Monitor/Modify Tx

palonosetron + gilteritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• haloperidol
Posfrea (palonosetron)

+

haloperidol

1 interaction

Monitor/Modify Tx

palonosetron + haloperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyzine
Posfrea (palonosetron)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

palonosetron + hydroxyzine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• imipramine
Posfrea (palonosetron)

+

imipramine

1 interaction

Monitor/Modify Tx

palonosetron + imipramine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• lapatinib
Posfrea (palonosetron)

+

lapatinib

1 interaction

Monitor/Modify Tx

palonosetron + lapatinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lasmiditan
Posfrea (palonosetron)

+

lasmiditan

1 interaction

Monitor/Modify Tx

palonosetron + lasmiditan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• lenvatinib
Posfrea (palonosetron)

+

lenvatinib

1 interaction

Monitor/Modify Tx

palonosetron + lenvatinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levalbuterol inhaled
Posfrea (palonosetron)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + levalbuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lofexidine
Posfrea (palonosetron)

+

lofexidine

1 interaction

Monitor/Modify Tx

palonosetron + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lumateperone
Posfrea (palonosetron)

+

lumateperone

1 interaction

Monitor/Modify Tx

palonosetron + lumateperone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lurasidone
Posfrea (palonosetron)

+

lurasidone

1 interaction

Monitor/Modify Tx

palonosetron + lurasidone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mavorixafor
Posfrea (palonosetron)

+

mavorixafor

1 interaction

Monitor/Modify Tx

palonosetron + mavorixafor

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mefloquine
Posfrea (palonosetron)

+

mefloquine

1 interaction

Monitor/Modify Tx

palonosetron + mefloquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• methylene blue injection
Posfrea (palonosetron)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

palonosetron + methylene blue injection

hold palonosetron if emergency use; monitor serotonin syndrome sx up to 4h after last methylene blue dose; may resume palonosetron 72h after last methylene blue dose: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• methylergonovine
Posfrea (palonosetron)

+

methylergonovine

1 interaction

Monitor/Modify Tx

palonosetron + methylergonovine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methylphenidate
Posfrea (palonosetron)

+

methylphenidate

1 interaction

Monitor/Modify Tx

palonosetron + methylphenidate

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• metoclopramide
Posfrea (palonosetron)

+

metoclopramide

1 interaction

Monitor/Modify Tx

palonosetron + metoclopramide

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• metronidazole
Posfrea (palonosetron)

+

metronidazole

1 interaction

Monitor/Modify Tx

palonosetron + metronidazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midostaurin
Posfrea (palonosetron)

+

midostaurin

1 interaction

Monitor/Modify Tx

palonosetron + midostaurin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• naratriptan
Posfrea (palonosetron)

+

naratriptan

1 interaction

Monitor/Modify Tx

palonosetron + naratriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nefazodone
Posfrea (palonosetron)

+

nefazodone

1 interaction

Monitor/Modify Tx

palonosetron + nefazodone

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ofloxacin
Posfrea (palonosetron)

+

ofloxacin

1 interaction

Monitor/Modify Tx

palonosetron + ofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Posfrea (palonosetron)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + olodaterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osilodrostat
Posfrea (palonosetron)

+

osilodrostat

1 interaction

Monitor/Modify Tx

palonosetron + osilodrostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Posfrea (palonosetron)

+

pasireotide

1 interaction

Monitor/Modify Tx

palonosetron + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• posaconazole
Posfrea (palonosetron)

+

posaconazole

1 interaction

Monitor/Modify Tx

palonosetron + posaconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pralsetinib
Posfrea (palonosetron)

+

pralsetinib

1 interaction

Monitor/Modify Tx

palonosetron + pralsetinib

monitor ECG; consider monitoring electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• primaquine
Posfrea (palonosetron)

+

primaquine

1 interaction

Monitor/Modify Tx

palonosetron + primaquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• promethazine
Posfrea (palonosetron)

+

promethazine

1 interaction

Monitor/Modify Tx

palonosetron + promethazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• protriptyline
Posfrea (palonosetron)

+

protriptyline

1 interaction

Monitor/Modify Tx

palonosetron + protriptyline

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• quinidine (CYP2D6 inhibitor)
Posfrea (palonosetron)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

palonosetron + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ranolazine
Posfrea (palonosetron)

+

ranolazine

1 interaction

Monitor/Modify Tx

palonosetron + ranolazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• relugolix
Posfrea (palonosetron)

+

relugolix

1 interaction

Monitor/Modify Tx

palonosetron + relugolix

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• rizatriptan
Posfrea (palonosetron)

+

rizatriptan

1 interaction

Monitor/Modify Tx

palonosetron + rizatriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• romidepsin
Posfrea (palonosetron)

+

romidepsin

1 interaction

Monitor/Modify Tx

palonosetron + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sacituzumab govitecan
Posfrea (palonosetron)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

palonosetron + sacituzumab govitecan

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• salmeterol inhaled
Posfrea (palonosetron)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + salmeterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• SAMe
Posfrea (palonosetron)

+

SAMe

1 interaction

Monitor/Modify Tx

palonosetron + SAMe

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• selpercatinib
Posfrea (palonosetron)

+

selpercatinib

1 interaction

Monitor/Modify Tx

palonosetron + selpercatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• St. John's wort
Posfrea (palonosetron)

+

St. John's wort

1 interaction

Monitor/Modify Tx

palonosetron + St. John's wort

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sumatriptan
Posfrea (palonosetron)

+

sumatriptan

1 interaction

Monitor/Modify Tx

palonosetron + sumatriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sunitinib
Posfrea (palonosetron)

+

sunitinib

1 interaction

Monitor/Modify Tx

palonosetron + sunitinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tacrolimus
Posfrea (palonosetron)

+

tacrolimus

1 interaction

Monitor/Modify Tx

palonosetron + tacrolimus

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tazemetostat
Posfrea (palonosetron)

+

tazemetostat

1 interaction

Monitor/Modify Tx

palonosetron + tazemetostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telavancin
Posfrea (palonosetron)

+

telavancin

1 interaction

Monitor/Modify Tx

palonosetron + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• terbutaline
Posfrea (palonosetron)

+

terbutaline

1 interaction

Monitor/Modify Tx

palonosetron + terbutaline

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tolterodine
Posfrea (palonosetron)

+

tolterodine

1 interaction

Monitor/Modify Tx

palonosetron + tolterodine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triclabendazole
Posfrea (palonosetron)

+

triclabendazole

1 interaction

Monitor/Modify Tx

palonosetron + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Posfrea (palonosetron)

+

trifluridine

1 interaction

Monitor/Modify Tx

palonosetron + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valbenazine
Posfrea (palonosetron)

+

valbenazine

1 interaction

Monitor/Modify Tx

palonosetron + valbenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vardenafil
Posfrea (palonosetron)

+

vardenafil

1 interaction

Monitor/Modify Tx

palonosetron + vardenafil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Posfrea (palonosetron)

+

vemurafenib

1 interaction

Monitor/Modify Tx

palonosetron + vemurafenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vilanterol inhaled
Posfrea (palonosetron)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

palonosetron + vilanterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voclosporin
Posfrea (palonosetron)

+

voclosporin

1 interaction

Monitor/Modify Tx

palonosetron + voclosporin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voriconazole
Posfrea (palonosetron)

+

voriconazole

1 interaction

Monitor/Modify Tx

palonosetron + voriconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• zolmitriptan
Posfrea (palonosetron)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

palonosetron + zolmitriptan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)